Poor sleep and elevation of liver function biomarkers may be predictive of liver cancer
1. Unhealthy sleep, as well elevations of liver enzymes and decreased levels of albumin and liver...
Read More
Oncology
Subcutaneous amivantamab with lazertinib is non-inferior to intravenous administration, with fewer adverse reactions
1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab...
Read More
Amivantamab and Lazertinib in Untreated EGFR-Mutated Advanced NSCLC
1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the...
Read More
Daratumumab linked to improved progression-free survival and MRD-negativity in transplant-eligible myeloma patients
1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction...
Read More
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced NSCLC
1. Patients with no biochemical or radiographic evidence of progressive disease had a median...
Read More
Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
1. Treatment with osimertinib significantly improved progression-free survival, compared to...
Read More
Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colon Cancer
1. No disease recurrences were observed during the median follow-up time of 26.2 months. 2....
Read More
Quantifying the reduction of primary breast cancer associated with exercise
1. Across a follow-up period of approximately 5 years, there was a non-linear relationship between...
Read More
Biparametric MRI Associated With Higher False Positive Rate than Prostate-Specific Antigen for Prostate Cancer Screening
1. In this decision model analysis, biparametric MRI (bpMRI) testing led to an increased rate of...
Read More
Long-term survival improved with use of tebentafusp for metastatic uveal melanoma
1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic...
Read More
Asciminib demonstrates superior efficacy for the treatment of CML in comparison to imatinib and second-generation TKIs
1. Asciminib demonstrated higher efficacy for the treatment of newly diagnosed CML than imatinib...
Read More
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1. The event-free survival at 12 months was 83.7% in the neoadjuvant group vs 57.2% in the...
Read More
Short-term androgen deprivation therapy does not improve survival in patients receiving postoperative radiotherapy for prostate cancer
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT...
Read More
Large language models (LLMs) demonstrated higher error rates compared to humans in a clinical oncology question bank
1. A comparative evaluation tested five publicly available LLMs on 2044 oncology questions,...
Read More
Perioperative Nivolumab in Resectable Lung Cancer
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the...
Read More
Genomic data optimizes hematopoietic stem-cell transplantation (HSCT) timing for myelodysplastic syndromes (MDS) and improves patient outcomes
1. A decision support system using the Molecular International Prognostic Scoring System (IPSS-M)...
Read More
Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer
In patients with metastatic prostate cancer, ARV-766 treatment led to a greater than 50% reduction...
Read More
Positron emission tomography-guided treatment strategy may reduce need for chemotherapy for patients with HER2+ breast cancer
1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There...
Read More
Remote electronic patient reported outcomes may have limited feasibility in older patients with cancer
1. Among patients on anticancer treatment with malignancy who were 75 years of age or older, the...
Read More
Capecitabine or XELOX did not appear to improve overall survival when compared to PF in patients with advanced Esophageal Squamous Cell Carcinoma
1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy...
Read More